David Charles, MD
Internal Medicine · Rockville, MDNPI 1487835179
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,556 of the $5,756 with a category attached, or 79.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,894 and has fallen 70.9% since, to $550 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AstraZeneca$1K
- AbbVie$753
- Novo Nordisk$484
- Lilly USA, LLC$416
- GSK$405
- plus $1K from 28 others
Across 6 payments — averaging $27,512 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$165K
What the payments were for
- Consulting fees$1,20021%
- Food & beverage$4,55679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 4 | $1,239 |
| AstraZeneca | 52 | $1,076 |
| AbbVie(2 entities) | 43 | $753 |
| Novo Nordisk | 24 | $484 |
| Lilly USA, LLC | 19 | $416 |
| GSK | 21 | $405 |
| Pfizer | 6 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $133 |
| Merck | 12 | $131 |
| Abbott | 7 | $120 |
| Astellas Pharma US Inc | 6 | $105 |
| Amgen(2 entities) | 5 | $90 |
| Gilead | 4 | $82 |
| Ironwood Pharmaceuticals, Inc | 4 | $82 |
| Boehringer Ingelheim | 3 | $48 |
| Antares Pharma, Inc. | 2 | $44 |
| Novartis | 3 | $42 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $23 |
| Bayer | 1 | $20 |
| Tolmar, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| CSL Behring | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $16 |
| Bausch Health US, LLC | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- UBRELVY$125
- BREZTRI$109
- FARXIGA$109
How this compares
$5,756 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $87,491 |
| JardianceEmpagliflozin | 43 | $55,957 |
| JanuviaSitagliptin Phosphate | 47 | $50,881 |
| MounjaroTirzepatide | 42 | $42,007 |
| FarxigaDapagliflozin Propanediol | 34 | $41,446 |
| EliquisApixaban | 34 | $32,032 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $29,077 |
| TrulicityDulaglutide | 19 | $22,964 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $20,157 |
| XareltoRivaroxaban | 15 | $19,610 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $19,202 |
| LinzessLinaclotide | 18 | $14,922 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $14,413 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $12,504 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $6,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $484 | $87,49182 claims |
| MerckJanuvia, Janumet | $131 | $79,95868 claims |
| Lilly USA, LLCMounjaro, Trulicity | $416 | $64,97261 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,076 | $60,64856 claims |
| Boehringer IngelheimJardiance | $48 | $55,95743 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $405 | $32,66143 claims |
| PfizerEliquis | $143 | $32,03234 claims |
| AbbVieLinzess, Synthroid | $753 | $16,29936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Rockville
- Scott KoenigRockville$20K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.